129 related articles for article (PubMed ID: 36728357)
21. Development and validation of LC-MS/MS methods for the quantification of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, and its main metabolite M6 in human plasma, urine and feces: Application to a clinical study in healthy Chinese subjects.
Gao H; Cheng M; Liu H; Ding L
J Pharm Biomed Anal; 2023 Sep; 233():115498. PubMed ID: 37285657
[TBL] [Abstract][Full Text] [Related]
22. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
23. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
24. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation.
Moreno-Vicente R; Fernández-Nieva Z; Navarro A; Gascón-Crespí I; Farré-Albaladejo M; Igartua M; Hernández RM; Pedraz JL
J Pharm Biomed Anal; 2015 Oct; 114():105-12. PubMed ID: 26037158
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients.
Cui X; Zheng X; Jiang J; Tan F; Ding L; Hu P
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Nov; 1068-1069():33-40. PubMed ID: 29028616
[TBL] [Abstract][Full Text] [Related]
28. Fast and Sensitive Analysis of Fosfomycin in Human Plasma Microsamples Using Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring.
Barone R; Conti M; Giorgi B; Gatti M; Cojutti PG; Viale P; Pea F
Ther Drug Monit; 2024 Jun; 46(3):384-390. PubMed ID: 38018880
[TBL] [Abstract][Full Text] [Related]
29. Dispersive liquid-liquid microextraction followed by sweeping micellar electrokinetic chromatography-tandem mass spectrometry for determination of six breast cancer drugs in human plasma.
Mlinarić Z; Turković L; Sertić M
J Chromatogr A; 2024 Mar; 1718():464698. PubMed ID: 38354504
[TBL] [Abstract][Full Text] [Related]
30. Systematic evaluation of matrix effect and cross-talk-free method for simultaneous determination of zolmitriptan and N-desmethyl zolmitriptan in human plasma: a sensitive LC-MS/MS method validation and its application to a clinical pharmacokinetic study.
Patel B; Suhagia BN; Jangid AG; Mistri HN; Desai N
Biomed Chromatogr; 2016 Mar; 30(3):447-58. PubMed ID: 26189757
[TBL] [Abstract][Full Text] [Related]
31. A validated enantioselective LC-MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study.
Furlong MT; Ji QC; Iacono L; Dang O; Noren M; Bruce J; Aubry AF; Arnold ME
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1022():167-172. PubMed ID: 27100678
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of a novel LC-MS/MS method for simultaneous quantitative determination of tyrosine kinase inhibitors in human plasma.
Lou Y; Qin H; Hu Q; Chai Y; Zhou H; Chen M; Wang Q; Huang P; Gu J; Zhang Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Oct; 1208():123394. PubMed ID: 35932695
[TBL] [Abstract][Full Text] [Related]
33. "A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring".
Soledad Poetto A; Posocco B; Zanchetta M; Gagno S; Orleni M; Canil G; Alberti M; Puglisi F; Toffoli G
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Sep; 1207():123403. PubMed ID: 35940043
[TBL] [Abstract][Full Text] [Related]
34. High sensitive LC-MS/MS method for estimation of eluxadoline in human plasma and its application to pharmacokinetic study.
Dodda S; Makula A; Polagani SR; Kandhagatla RN
J Pharm Biomed Anal; 2019 Feb; 165():65-72. PubMed ID: 30502553
[TBL] [Abstract][Full Text] [Related]
35. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
36. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
37. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment.
Li J; Jiang J; Wu J; Bao X; Sanai N
Clin Pharmacol Ther; 2021 Feb; 109(2):494-506. PubMed ID: 32799335
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.
Tong F; Lu Y; Ma HF; Shen J
Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268
[TBL] [Abstract][Full Text] [Related]
39. Simple and rapid quantification of ribociclib in rat plasma by protein precipitation and LC-MS/MS: An application to pharmacokinetics of ribociclib nanoparticles in rats.
Alshogran OY; Al-Shdefat R; Hailat M
J Mass Spectrom; 2023 Dec; 58(12):e4984. PubMed ID: 37950646
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous quantification of 19 analytes in breast milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Monfort A; Jutras M; Martin B; Boucoiran I; Ferreira E; Leclair G
J Pharm Biomed Anal; 2021 Sep; 204():114236. PubMed ID: 34273657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
